An interventional study of Questionnaire and Physical Exam and Questionnaire and Physical Exam in Neuropsychological Tests, Memory and Alzheimer Disease, sponsored by Poitiers University Hospital. Suspended at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Poitiers University Hospital · Not applicable, Interventional, and Other
Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).
To date, neuropsychological assessment of deaf signing persons is complicated by a lack of resources, especially the absence of tools available in French Sign Language (LSF). This is due to perceptual and cultural differences, and in particular the linguistic differences between French and LSF.
This lack of resources significantly hinders access to care for deaf patients, as neuropsychological assessment is often a key clinical criterion in the diagnosis of certain neurological pathologies (Alzheimer's disease in particular) and enables coherent care plans to be drawn up, for example in the aftermath of strokes or traumatic brain injuries.
In particular, episodic memory (which refers to the ability to memorise information anchored in a specific context) is a cognitive domain that is sensitive to pathologies such as Alzheimer's disease, but it is not currently possible to assess it with deaf signing patients.
The aim of this study is to create a memory assessment test adapted to a deaf population that expresses in LSF and to normalize this test on this same population.
The aim is to provide a diagnosis assessment tool, which currently does not exist in France, to improve access to care for deaf people. This project could then be extended to the creation of tests for other cognitive domains (executive functions, attention, social cognition, etc.) and to prospects for cognitive remediation.
The 16-item Free and Cued Recall test (RL-RI 16) is the best choice because it is easy to use and accurate enough to assess each stage of episodic memory. These qualities make it a decisive tool in certain differential diagnosis.
Phase 1: In order to select the most relevant signs, lexical lists by frequency in LSF will be drawn up during a preliminary phase, during which the participants will have to give, in one minute, the maximum number of signs belonging to different categories (animals, vegetables, clothes...). These lists will be used to select the most relevant signs according to their frequency (neither too common nor too rare), based on the same principle as RL-RI 16.
Phase 2: It will then be standardised on deaf adults, for whom LSF is the main language, with no cognitive impairment, across France, via the various Deaf Care Units, with the help of French / LSF interpreters. Working with different centers in France will make it possible to recruit a larger and more representative number of participants, and to be more sensitive to any regional effects.
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 120 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Poitiers University Hospital is the lead sponsor of 314 studies on the registry; 62 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 16, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Non-inclusion Criteria:
Exclusion Criteria (post-inclusion):
- A score ≤ 20/28 or 17/28 at the MMS-LS test, depending on the schooling of the participant (20/28 for participants with a degree, 17/28 for participants without a degree)
Other: Questionnaire and Physical Exam
Phase 1: Single-visit with assessment of cognitive performance (MMS-LS) and fluency tasks (verbal flexibility)
Phase 2: * Inclusion visit (M0) with assessment of cognitive performance (MMS-LS), administration of the RL-RI-LSF test, Rey-Osterrieth complex figure and WAIS-IV subtests (matrix reasoning, symbol search, coding). * Follow-up visit (M9) with assessment of cognitive performance (MMS-LS), administration of the RL-RI-LSF test, Rey-Osterrieth complex figure and WAIS-IV subtests (matrix reasoning, symbol search, coding).
RL-RI-LSF scores for a deaf population without cognitive impairment
The primary objective is to establish standardized data for the RL-RI-LSF test (adaptation in FSL of the RL-RI 16 test) for a deaf population without cognitive impairment. The RL-RI-LSF scores correspond to the number of signs correctly recalled by the patient during each recall: immediate recall, free recalls, total recalls, recognition scores
Time frame: At inclusion of the Phase 2
Association between RL-RI-LSF scores and MMS-LS score
Correlation coefficient between the MMS-LS and each score of the RL-RI-LSF test will be provided
Time frame: At inclusion for Phase 2
Reliability (test/retest) of the RL-RI-LSF after 9 months
Intraclass correlation coefficient for each RL-RI-LSF score will be provided. RL-RI-LSF score will be assessed at inclusion and after a 9-months interval.
Time frame: At inclusion and after 9 months for Phase 2
Rey-Osterrieth complex figure scores
The investigators plan to expand the standardized data of the Rey-Osterrieth complex figure among deaf subjects without cognitive impairment, as a continuation of the work initiated by a team in Lille Hospital. The following scores are considered: visuo-spatial copying, immediate recall, delayed recall, recognition.
Time frame: At inclusion of the Phase 2
WAIS-IV subtests (Matrix reasoning, Symbol Search, Coding)
To establish standardized data for 3 subtests of the WAIS-IV for a deaf population without cognitive impairment. The following subtests will be considered: matrix reasoning, symbol search, coding.
Time frame: At inclusion of the Phase 2
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started May 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Apr 2025 → May 2025, primary completion Jan 2027 → Nov 2027 and completion Apr 2027 → Aug 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).
Inclusions suspended during the period between phase 1 (adaptation of the test in French sign Language) and phase 2 (inclusion for the standardization of the test).
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Poitiers University Hospital →